Minerva Neurosciences, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; comparisons are with FY2021. This is an annual report, not a standalone fourth-quarter results filing. Minerva is a clinical-stage CNS biopharmaceutical company with no approved products and no product-sales revenue.
Business context and development
- Roluperidone: Lead candidate for negative symptoms of schizophrenia. The company submitted an NDA in August 2022, but the FDA issued a refusal-to-file letter in October and confirmed after a November Type A meeting that the refusal remained in effect. The company said it expected further FDA discussions.
- Evidence submitted included a positive Phase 2b study and a Phase 3 study whose primary intent-to-treat analysis narrowly missed statistical significance (p=0.064). A modified analysis excluding 17 patients from a site with implausible data showed nominal statistical significance (p=0.044).
- MIN-301: Parkinson’s disease program remained deferred in 2022 as Minerva prioritized roluperidone; no development updates were reported. The company recorded a $15.2 million non-cash impairment in 2021.
- Seltorexant: Janssen continued two Phase 3 studies; a third was discontinued during 2022. Minerva sold its royalty rights to Royalty Pharma in 2021 for $60 million upfront and up to $95 million in contingent milestones.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $14.6 million | $32.0 million |
| General and administrative expense | $10.6 million | $13.3 million |
| Total expenses / operating loss | $25.2 million / $(25.2) million | $45.4 million / $(45.4) million |
| Non-cash interest expense on royalty-sale liability | $7.4 million | $6.3 million |
| Net loss | $(32.1) million | $(49.9) million |
| Net loss per share | $(6.01) | $(9.35) |
| Cash used in operating activities | $24.6 million | $24.6 million |
- R&D expense fell mainly because FY2021 included the $15.2 million MIN-301 impairment and roluperidone trial costs were lower after completion of the 40-week open-label extension. G&A declined primarily due to lower staffing, legal and insurance costs.
- Cash, cash equivalents and restricted cash were $36.2 million at year-end, down from $60.9 million. The company said this was sufficient for operating commitments for at least 12 months from issuance of the financial statements. It also stated that additional capital will be needed to continue operations and fund later-stage development.
- Working capital included a $3.1 million refundable FDA fee, received in January 2023. The company reported total assets of $55.1 million, total liabilities of $75.1 million and a stockholders’ deficit of $20.0 million at year-end.
- The $73.7 million liability related to the sale of future seltorexant royalties is accounted for as debt financing; it is the principal reported financing liability. The effective annual interest rate was estimated at approximately 10.7% at December 31, 2022. The filing describes recourse to Minerva relating to payments due from Janssen, although payments from Royalty Pharma are not repayable merely because Janssen discontinues development or commercialization.
- No meaningful operating margin is available because the company had no product-sales revenue. The filing does not provide a clear revenue-based margin measure.
Outlook, risks and unusual items
- No specific revenue, earnings or development guidance was provided. Management’s outlook is contingent on further FDA discussions, available funding and the timing and outcomes of clinical and regulatory work.
- In January 2023, the FDA refunded the approximately $3.1 million NDA fee under a small-business waiver. The amount was recorded as a refundable fee at year-end.
- Minerva had a Nasdaq minimum market-value deficiency: its listed-securities market value had been below $35 million for 30 consecutive business days. The stated compliance deadline was May 30, 2023; failure to regain compliance could lead to delisting. The company had previously completed a 1-for-8 reverse split and moved from the Nasdaq Global Market to the Nasdaq Capital Market in September 2022.
- Key risks include continued losses and financing needs; uncertainty about the roluperidone NDA and additional evidence the FDA may require; reliance on external clinical and manufacturing providers; and uncertainty over seltorexant milestones and the royalty liability estimates. The company reported nine full-time employees and no product liability insurance.
- Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2022. The auditor issued an unqualified opinion on the financial statements but did not attest to ICFR, consistent with the company’s reporting status.
Most important facts for investors to verify
- What specific deficiencies or additional data the FDA requires for roluperidone, and whether Minerva can address them with available resources.
- Cash runway after the January 2023 fee refund, expected spending and financing options; the stated runway is at least 12 months from the financial-statement issuance date, not a guarantee of longer-term funding.
- Progress and outcomes of Janssen’s two remaining seltorexant Phase 3 studies, contingent Royalty Pharma milestones and assumptions underlying the $73.7 million royalty-sale liability.
- Whether Minerva regained Nasdaq’s $35 million market-value requirement by the May 30, 2023 deadline and its subsequent listing status.
- Whether MIN-301 remains deferred and whether any further impairment or strategic portfolio changes are reported.